New 2016 Clinical Practice Guidelines for the Management of Candidiasis

Just a little "light" reading on this evening at the end of December, 2015.
The IDSA (Infectious Disease Society of America) just published new Clinical Practice Guidelines for the Management of Candidiasis. This 2016 update lists 15 distinct Candida species that cause human disease, but 90% of invasive disease is caused by the 5 most common pathogens, Candida albicans, Candida glabrata, Candida tropical, Candida parapsilosis and Candida krusei.

Each organism has unique virulence potential, anti-fungal susceptibility and epidemiology, but taken as a whole, significant infections due to these organisms are generally referred to as invasive candidiasis. Many medications are listed, with recommendations for the treatment of candida infections, but they are really just best guesses, and anti-fungal therapy often results in relapse.

It further states that infections due to Candida species are major causes of morbidity and mortality in humans, causing a diverse spectrum of clinical diseases ranging from superficial and mucosal infections to invasive disease associated with candidemia and metastatic organ involvement. Candidemia is one of the most common healthcare-associated bloodstream infections in US hospitals. Blood cultures are notoriously insensitive as markers of disease, and this remains a significant obstacle to early diagnosis and intervention for this condition.
In randomized, controlled trials examining treatment of candidemia and other forms of invasive candidiasis, no single trial has demonstrated clear superiority of one therapeutic agent over another, often times leading to conflicting conclusions. Recent studies of anti-fungal resistance in Candida species suggest that itraconazole, voriconazole and posaconazole resistance among Candida glabrata isolates has increased to the degree that it is difficult to rely upon these agents for therapy in the absence of susceptibility testing.

As I read about Central Nervous system candida infection, Intra-abdominal candidiasis, Intravascular, Osteoarticular (bones & joints) and respiratory tract colonization of candida species, which is associated with the development of pneumonia, with the worse clinical outcomes and higher mortality, it makes me wonder how I survived for 30 years with this, in all it's forms, and why I am still here?

I have intensively researched Candida extensively for 30 years. My sole motivation was to save my own life. Doctors and drugs were absolutely worthless, as through countless years of trial and error, I tried almost all of them. One example of a drug I am glad not to have used is Lufeneron.

Candida has been abandoned by the medical profession, and misdiagnosed by doctors. Many companies have taken advantage of this void by selling products that will make a profit for them, but do relatively nothing for the Candida sufferer. They promise a cure, but fail to deliver.
The promotion of Lufenuron is an example of promising a cure, while discouraging the use of anything else, in an attempt to steer people away from following sound advise or common sense. Here are the facts about using Lufeneron to treat Candida.

My research has revealed that Lufeneron is a benzoylurea pesticide that interferes with the chitin making process in the candida cell. Chitin is needed to form a hard outer shell - exoskeleton. For this reason, Lufeneron is an ingredient in veterinary flea, heart worm control and anthelmintic medications for dogs and cats. It does not kill adults, so this sets up a dependency on the drug to keep killing the offspring. It is also sold as an agricultural pesticide and anti fungal for plants. It is marketed to desperate people as an effective anti-fungal, due to it’s ability to act as a chitin synthesis inhibitor, but the Candida are not so cooperative as marketers would like to believe.

Chitin is found in Candida cell walls in varying degrees, depending on the environmental stresses that candida encounters. Candida has the ability to manipulate the chitin content in its cell wall membranes. In the presence of chitin inhibitors, it will alter it’s chitin content to preserve the integrity of its cell wall membrane.

The initial science demonstrated a possible role in affecting Candida fungal growth, but subsequent studies dismissed it. Science shows Lufenuron doesn’t work against Candida, but the later reports were not made known to the public. Promoters of Lufenuron want you to believe that candida doesn’t have the ability to manipulate the chitin content in it's cell wall membranes. However, you must know our enemy to defeat them.

Another reason I am glad not to have used Lufenuron is its affect on intestinal membranes, causing leaky gut. It disturbs the epithelial barrier and epithelial transport processes, which can be a major factor in the pathogenesis of intestinal inflammation and inflammatory bowel diseases. The intestinal epithelium is a barrier that protects you from enteric pathogens, food antigens, physiochemical stresses caused by digestive and microbial products and other assaults from the external environment. Tightly regulated control of this barrier function and integrity, to keep out things that would harm you, yet be selectively permeable to beneficial nutrients and fluids, is critical for your survival. The pathogenesis of intestinal diseases are linked to intestinal barrier dysfunction and increased intestinal permeability. Intestinal disease predisposes to every other chronic disease condition in the human body. Lufenuron interferes with the formation of cell walls in many beneficial bacteria, thus interfering with the structure of healthy intestinal bacteria.

Lufenuron also said to cause female reproduction problems. Lufenuron builds up in tissues, especially fat. Adverse effects have been reported in dogs and cats after oral Lufenuron: vomiting, lethargy, depression, diarrhea, anorexia, skin redness, pruritus/urticaria. Using an insecticide designed for animals, in humans, is not something I would recommend.

Any approach in restoring balance to the intestinal flora, immune response and candida overgrowth, should take into consideration the whole body. Candida doesn’t exist in an isolated area of the body, like the intestines. It takes up residence in the deep tissues, where nothing can reach it. There it lays in wait for you to get off your Candida killing drug or herb and comes back out at you with a vengeance. For this reason, attempts to kill Candida present with short-lived results at best, but they frequently cause more harm to the body in the process.

Trying to “kill” Candida only makes it adapt and become more resilient. The program I use corrects fungal Candida imbalances by safely returning the fungal form of candida back to its normal yeast form, healing the intestinal lining, helping to restore healthy bacterial flora, detoxifying the body, and restoring the immune system. This is a whole body approach that awakens the body’s innate ability to heal, regulate, balance and protect itself. Anything that doesn’t activate the life-force that is present in every cell in your body, doesn’t promote health and the potential for a long life.

Lufenuron is a dangerous drug that creates resistant strains of Candida, while at the same time damaging your intestinal lining, causing leaky gut, and damaging the beneficial bacteria in the gut that are a major component of mucosal immunity. It collects in muscle and fat tissue, so it will take a very long time to detoxify from the body, once its use is discontinued. It's effects will be long term, until it clears from your body completely.

Alternative treatments have limitations, as I discovered with great disappointment. How could I, with my limited resources and education, figure this thing out? God! The Great Physician guided me.

If you have questions, email to schedule your free introductory consultation. I look forward to serving you. JVW